Literature DB >> 3086743

Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system.

M B Oldstone, P Blount, P J Southern, P W Lampert.   

Abstract

The mechanism(s) by which infectious or malignant material is cleared by the host has long been an area of intensive study. We have used the murine model of infection with lymphocytic choriomeningitis virus (LCMV) to look at immune clearance during persistent infection. LCMV was selected because the mouse is its natural host, it easily induces acute or persistent infection in vivo, and the mechanism by which it is cleared in vivo during acute infection is now well understood. Clearance, although associated with several antiviral immune effector mechanisms, is primarily dependent on the activity of virus-specific cytotoxic T lymphocytes (CTL) restricted by H-2 molecules of the mouse major histocompatibility complex (MHC). If these cells fail to generate or are depleted, progression from acute to persistent infection occurs. Here, using molecular probes, we show that viral nucleic acid sequences, viral proteins and infectious materials can be efficiently and effectively cleared by adoptive transfer of antiviral H-2-restricted lymphocytes bearing the Lyt 2+ phenotype. Viral materials are cleared from a wide variety of tissues and organs where they normally lodge during persistent infection. Unexpectedly, the mode by which viral materials are removed from the central nervous system (CNS) differed markedly from the mechanism of clearance occurring at other sites. These observations indicate the possible use of adoptive lymphocyte therapy for treatment of persistent infections and suggest that immune clearance of products from the CNS probably occurs by a process distinct from those in other organs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086743     DOI: 10.1038/321239a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  111 in total

1.  Diversity of T-cell receptors in virus-specific cytotoxic T lymphocytes recognizing three distinct viral epitopes restricted by a single major histocompatibility complex molecule.

Authors:  Y Yanagi; A Tishon; H Lewicki; B A Cubitt; M B Oldstone
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  The Anatomy of a Career in Science.

Authors:  Michael B A Oldstone
Journal:  DNA Cell Biol       Date:  2016-02-02       Impact factor: 3.311

3.  Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection.

Authors:  K E Wright; M J Buchmeier
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

Review 4.  Molecular anatomy of viral persistence.

Authors:  M B Oldstone
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

5.  Trojan horse lymphocytes: a vesicular stomatitis virus-specific T-cell clone lyses target cells by carrying virus.

Authors:  R C Hom; G Soman; R Finberg
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

6.  Genetic analysis of in vivo-selected viral variants causing chronic infection: importance of mutation in the L RNA segment of lymphocytic choriomeningitis virus.

Authors:  R Ahmed; R S Simon; M Matloubian; S R Kolhekar; P J Southern; D M Freedman
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

7.  IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection.

Authors:  David G Brooks; Sang-Jun Ha; Heidi Elsaesser; Arlene H Sharpe; Gordon J Freeman; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

8.  Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence.

Authors:  M Salvato; P Borrow; E Shimomaye; M B Oldstone
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

9.  Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection.

Authors:  Kevin B Walsh; David Marsolais; Megan J Welch; Hugh Rosen; Michael B A Oldstone
Journal:  Virology       Date:  2009-12-03       Impact factor: 3.616

Review 10.  Sites of antigen presentation in T-cell mediated demyelinating diseases.

Authors:  P T Massa
Journal:  Res Immunol       Date:  1989-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.